Lung Cancer

DUBLIN-The shift from histologic classification to molecular analysis of bronchial epithelial cells is opening up new prospects for detecting the molecular signature of lung cancer before the disease becomes clinically evident, James L. Mulshine, MD, of the National Cancer Institute, said at the 8th World Conference on Lung Cancer.

BETHESDA, Md-The Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) has recommended approval of QLT Photo-Therapeutics’ Photofrin (porfimer sodium) for use as photodynamic therapy (PDT) of T1 stage endobronchial carcinoma in patients with non-small-cell lung cancer (NSCLC) for whom surgery and radiotherapy are not indicated.

Breast cancer is second only to lung cancer as a leading cause of cancer mortality in women. In women with metastatic, hence, essentially incurable disease, we strive to find effective chemotherapeutic regimens that offer a

Given that no therapeutic methods of postoperative adjuvant chemotherapy for non-small-cell lung cancer have been established, we selected UFT (tegafur and uracil) for investigation because UFT is less injurious to the host

A single-institution phase II study indicated that combination chemotherapy using UFT (tegafur and uracil) plus cisplatin (Platinol) in patients with non-small-cell lung cancer was active with less host toxicity than other cisplatin-

The article by O'Donovan discusses the radiologic appearance of lung cancer, with particular emphasis on the radiographic appearance and work-up of solitary pulmonary nodules (SPNs).

NEW YORK-Today’s treatments for lung cancer are much better tolerated than treatments used 20 years ago, Robert Ginsberg, MD, chief of the Thoracic Service, Memorial Sloan-Kettering Cancer Center, said at an NIH video satellite symposium beamed to 20 selected centers nationwide.

It should be noted that the most common presentation of asymptomatic lung cancer is indeed a solitary pulmonary nodule (SPN), but for most symptomatic lung cancers the nodule is at least 3 cm in diameter at the time of initial diagnosis. The author does a good job of providing documentation to refute one of his critical hypotheses, which indicates that "neoplasm can often be strongly suspected or excluded based on the radiologic characteristics of the single pulmonary nodule."

Treatment of patients with unresectable stage IIIA and IIIB non-small-cell lung cancer with conventionally-fractionated radiation therapy (ie, total doses of 50 to 60 Gy, using one fraction per day), which was standard

Better efficacy of chemotherapy for small-cell lung cancer (SCLC) has not been convincingly demonstrated despite many investigations examining increased drug

The objectives of this review are to provide an update and perspectives on the use of induction therapy (chemotherapy with or without radiotherapy) followed by surgery in two subgroups of patients with stage III non-

It is now established that the treatment of choice for limited small-cell lung cancer (SCLC) in the United States, Canada, and Japan is thoracic radiotherapy (TRT)

A solitary pulmonary nodule (SPN) is the most common radiographic presentation of lung cancer. The imaging characteristics of solitary pulmonary nodules are described and illustrated. The appearance and implications of

Docetaxel (Taxotere) and vinorelbine (Navelbine) have both demonstrated activity as single agents for the treatment of patients with metastatic breast cancer and non-small-cell lung

Docetaxel (Taxotere) is a semisynthetic taxoid that possesses significant activity as a single agent in the treatment of patients with non-small-cell lung cancer. In previously untreated patients with non-small-cell lung

BETHESDA, Md--Between 1960 and 1990, there has been a greater than 400% increase in deaths from lung cancer in women. "Women now account for about 45% of all new cases of lung cancer, a proportion that was only about 20% to 25% in the 1970s," said James Jett, MD, co-director of the Lung Cancer Program at the University of Pittsburgh.

In the United States, an estimated 178,000 new cases of lung cancer will occur in 1997, accounting for 13% of cancer diagnoses and 29% of all cancer deaths.[1] The majority of these deaths will be due to metastatic non-small-cell lung cancer. Cisplatin (Platinol), vindesine (Eldisine), vinblastine, ifosfamide (Ifex), and mitomycin (Mutamycin) demonstrate response rates of 15% or higher in previously untreated patients (Table 1)

There are few options availablefor the patient with advanced non-small-cell lung cancer in whom first-linechemotherapy has failed. Docetaxel (Taxotere), a semisynthetic taxoid,is one of the few drugs that has been systematically investigated as asecond-line option for patients with advanced non-small-cell lung cancer.

Docetaxel (Taxotere) andcarboplatin (Paraplatin) have each demonstrated significant activity in

Four phase II trials have beenconducted to evaluate the efficacy and tolerability of single-agent docetaxel

Docetaxel (Taxotere) isa semisynthetic taxoid that possesses significant activity as a single

Docetaxel (Taxotere) hasdemonstrated significant activity as a single agent in the treatment of

Researchers at The University of Texas M. D. Anderson Cancer Center have found that changes in a certain chromosome may indicate lung cancer susceptibility and may be linked to a family history of cancer.

SAN DIEGO--A therapy for advanced lung cancer patients who have not responded to other treatments is showing promise in studies at M.D. Anderson Cancer Center. In this phase I trial, 18 patients with non-small-cell lung cancer (NSCLC) and missing or defective copies of the tumor-suppressor p53 gene have received injections directly into their tumors of an adenovirus containing the p53 wildtype gene.

VANCOUVER, Wa--Lung cancer is the leading cause of cancer-related deaths in the United States, yet there are no colored ribbons for survivors and supporters, no races for a cure, and until now, no day, week, or month dedicated to lung cancer awareness.

The Society of Surgical Oncology surgical practice guidelines focus on the signs and symptoms of primary cancer, timely evaluation of the symptomatic patient, appropriate preoperative evaluation for extent of disease, and role of the surgeon in

BOCA RATON, Fla--Docetaxel (Taxotere) is showing promising single-agent activity in non-small-cell lung cancer (NSCLC), said James Rigas, MD, director, Thoracic Oncology Program, Norris Cotton Cancer Center, Dart-mouth-Hitchcock Medical Center (Lebanon, NH).

NEW YORK--Cancer Care, Inc. is offering a new booket, Learning About Lung Cancer: It Helps to Understand, that attempts to close the "information gap" with regard to how lung cancer is diagnosed and treated, as well as provide help and tips on how to cope with medical and nonmedical issues faced by lung cancer patients.

VIENNA--Although the majority of patients with advanced non-small-cell lung cancer (NSCLC) are too ill to tolerate platinum therapy, the more benign safety profile of gemcitabine (Gemzar) is opening up the possibility of palliative chemotherapy for a wider group of NSCLC patients.

A total of 332 patients with advanced non-small-cell lung cancer were randomized by the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative